Agmatine is an endogenous neuromodulator that has been shown to have antidepressant-like properties. We have previously demonstrated that it can induce a rapid increase in BDNF levels after acute administration, suggesting that agmatine may be a fast-acting antidepressant. To investigate this hypothesis, the present study evaluated the effects of a single administration of agmatine in mice subjected to chronic unpredictable stress (CUS), a model of depression responsive only to chronic treatment with conventional antidepressants. The ability of agmatine to reverse CUS-induced behavioral and biochemical alterations was evaluated and compared with those elicited by the fast-acting antidepressant (ketamine) and the conventional antidepressant (fluoxetine). After exposed to CUS for 14 days, mice received a single oral dose of agmatine (0.1 mg/kg), ketamine (1 mg/kg) or fluoxetine (10 mg/kg), and were submitted to behavioral evaluation after 24 h. The exposure to CUS caused an increased immobility time in the tail suspension test (TST) but did not change anhedonic-related parameters in the splash test. Our findings provided evidence that, similarly to ketamine, agmatine is able to reverse CUS-induced depressive-like behavior in the TST. Western blot analyses of prefrontal cortex (PFC) demonstrated that mice exposed to CUS and/or treated with agmatine, fluoxetine or ketamine did not present alterations in the immunocontent of synaptic proteins [i.e. GluA1, postsynaptic density protein 95 (PSD-95) and synapsin]. Altogether, our findings indicate that a single administration of agmatine is able to reverse behavioral alterations induced by CUS in the TST, suggesting that this compound may have fast-acting antidepressant-like properties. However, there was no alteration in the levels of synaptic proteins in the PFC, a result that need to be further investigated in other time points.
Stressful life experiences are important etiological factors in the onset and maintenance of depressive episodes (Lee et al., 2002) . Clinical and preclinical studies have demonstrated that chronic stress causes neuronal atrophy and cell loss in specific brain structures, particularly in the prefrontal cortex (PFC) and hippocampus. The deleterious effects of stress in these structures impair their function, leading to the deficits in cognitive and emotional processes observed in depressive patients (Drevets et al., 1997; Rajkowska et al., 1999; Sacher et al., 2012) . Based on these findings, stress-induced animal models have been proposed to mimic behavioral, neurochemical, neuroimmune and neuroendocrine alterations that resemble those observed in clinical depression (Cryan and Holmes, 2005; Willner, 1997) . Chronic unpredictable stress (CUS) is one of the most widely used animal models for the investigation of pathophysiological mechanisms underlying depression and the efficacy of new antidepressants (Willner, 1997 (Willner, , 2005 Willner and Mitchell, 2002) . This experimental model is based on the repeated exposure of rodents to distinct stressors for several weeks, which leads to behavioral alterations that mimic specific endophenotypes of depression such as an anhedonic behavior and an increased immobility time in behavioral despair tests [i.e. tail suspension test (TST) and forced swimming test (FST)] Manosso et al., 2016; Moretti et al., 2012; Willner, 2005) . Besides inducing depressive-like behaviors, CUS leads to decreased levels of proteins that participate in glutamate neurotransmission and have a key role in synaptic plasticity, by modulating GluA1 subunit of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, synapsin I and postsynaptic density protein 95 (PSD-95) . Of note, these deleterious effects in behavior and synaptic plasticity of rodents induced by CUS can be reversed only by the chronic administration of conventional antidepressants, (Banasr and Duman, 2007; Willner, 2005) .
Although the treatment of depression with monoaminergic antidepressants that act by increasing monoamine levels in the synaptic cleft has been used for many years, it has several drawbacks. These drugs are associated with the occurrence of side effects and need several weeks of treatment for improving the depressive symptoms (Berton and Nestler, 2006; Grunebaum et al., 2004) . For these reasons, there is a demand for antidepressants capable of triggering a fast-acting response with fewer side effects. Within this context, several studies have been demonstrating that a single infusion with a subanesthetic dose of ketamine, an N-methyl-D-aspartate (NMDA) receptors antagonist, causes a rapid antidepressant action in patients resistant to conventional treatment (Berman et al., 2000; Zarate et al., 2006) . Interestingly, a single administration of ketamine is able to reverse behavioral impairments induced by CUS in rats as assessed by the FST, learned helplessness (LH) paradigm, and novelty suppressed feeding test (NSFT) (Li et al., 2010) . Furthermore, this rapid rescue of depressive-like behaviors in preclinical studies is accompanied by the reestablishment of synaptic plasticity in the prefrontal cortex of rats submitted to CUS, an effect mediated by the stimulation of mammalian target of rapamycin (mTOR) signaling pathway (Duman, 2014; Duman et al., 2012) . However, the use of ketamine presents limitations that include a potential for abuse, psychotomimetic effects, tolerance and neurotoxicity upon repeated use (Behrens et al., 2007) .
Taking into account the limitations of ketamine use, the investigation of drugs that might share similar mechanisms with ketamine emerge as a promising therapeutic approach. In this scenario, our group has been investigating the antidepressant-like effects of agmatine, a neuromodulator synthesized by decarboxylation of Larginine (Piletz et al., 1995) . We have shown that agmatine is able to produce an antidepressant-like effect in mice submitted to the FST and TST, an effect that is dependent, at least partially, on the inhibition of NMDA receptors (Zomkowski et al., 2002) . We also provided evidence that agmatine exerts a synergistic antidepressant-like effect with MK-801 (a noncompetitive NMDA receptor antagonist) augmentating the antidepressant-like effect of this drug up to 100 fold Neis et al., 2015) . Considering that, similarly to ketamine, agmatine might have fast-acting antidepressant properties by rapidly increasing brain derived neurotrophic factor (BDNF) levels (Meylan et al., 2016; Neis et al., 2016) , the current study sought to investigate whether a single administration of agmatine is able to reverse behavioral and biochemical alterations induced by CUS paradigm, comparing its effects with a fast-acting (ketamine) and a conventional antidepressant (fluoxetine).
Material and methods

Animals
Considering that the prevalence of depression is about two fold higher in women than in men (Wong and Licinio, 2001 ) and that females are shown to be more susceptible to stress than males (Yoshimura et al., 2003) , this study was performed using adult female Swiss mice (30-40 g). The protocol was approved by the Ethics Committee of the Federal University of Santa Catarina (Protocol number 00795). Animals were maintained at 20-22°C with free access to water and food, under a 12:12 h light/dark cycle (lights on at 07:00 h). All behavioral tests were carried out between 9:00 a.m. and 04:00 p.m. All efforts were made to minimize animal suffering and to reduce the number of animals used in the experiments.
Drugs and treatment
Agmatine, fluoxetine and ketamine (obtained from Sigma Chemical Co., St. Louis, U.S.A) were dissolved in distilled water and administered orally (p.o.) in a single dose (0.1, 10 and 1 mg/kg respectively) 5 h after the last CUS procedure (day 14). All the drugs were freshly prepared before administration and administered in a volume of 1 ml/kg. To develop this study, mice were divided into eight groups, as follows: (1) non-stressed + vehicle; (2) non-stressed + agmatine; (3) nonstressed + ketamine; (4) non-stressed + fluoxetine; (5) stressed + vehicle; (6) stressed + agmatine; (7) stressed + ketamine; (8) stressed + fluoxetine. Fig. 1 shows a schematic representation of the treatment regime, behavioral and biochemical evaluation in our experimental model.
Chronic unpredictable stress (CUS) protocol
CUS protocol was adapted from Lu et al. (2006) and consisted of a variety of stressors randomly applied at different times of day for 14 days to prevent habituation (Table 1 ). Mice were divided into a control group (non-stressed) and a stressed group, which were maintained in separate rooms to avoid the interference of stress odors. Control and stressed mice were weighed once a week. Animals received a single administration of agmatine, ketamine, fluoxetine or vehicle 5 h after the last stressor and were submitted to behavioral evaluation 24 h after treatments. Mice were euthanatized by decapitation immediately after the behavioral tests, and prefrontal cortices were collected for biochemical analysis (Fig. 1) .
As shown in Table 1 , the following stressors were used in the CUS procedure: restraint, cold swim, wet wood shaving/box housing titled, cold restraint, tail pinch, swim, and inescapable footshock. Forced swimming, was carried out by placing the animals in an open cylindrical container (diameter 10 cm, height 25 cm) containing 19 cm of water at 25 ± 1°C or 15 ± 1°C. The footshock was applied in an apparatus consisting of a 50 × 25 × 25 cm plastic box with a front glass wall and parallel 10-mm bronze bars in the floor. Mice were gently placed on the grid and received a scrambled 0.7-mA, 0.5 s/min footshock during 3 min. Tail pinch was performed by applying a clothespin placed at 1 cm from the base of the tail, as previously described (Lu et al., 2006) .
Behavioral tests
Tail suspension test (TST)
The total duration of immobility induced by tail suspension was measured according to the method described by Steru et al. (1985) . Briefly, mice were suspended 50 cm above the floor by adhesive tape placed approximately 1 cm from the tip of the tail. Immobility time was manually recorded during a 6-min period by an experienced observer blind to the animal condition Neis et al., 2016) .
Open-field test (OFT)
The ambulatory behavior was assessed in an open-field test as described previously (Kaster et al., 2005) . The apparatus consisted of a wooden box measuring 40 × 60 × 50 cm high. The floor of the arena was divided into 12 equal rectangles. The number of rectangles crossed with all paws (crossing) was counted in a 6-min session. The apparatus was cleaned with a solution of 10% ethanol between tests in order to hide animal clues.
Splash test
Ten minutes after the OFT, the splash test was carried out. This test consists of squirting a 10% sucrose solution on the dorsal coat of a mouse placed individually in clear Plexiglas boxes (9 × 7 × 11 cm) (Moretti et al., 2012) . Because of its viscosity, the sucrose solution dirties the mouse fur and animals initiate grooming behavior. After applying sucrose solution, the time spent grooming was manually recorded for a period of 5 min as an index of self-care motivational behavior, considered to be parallel with some symptoms of depression such as apathetic behavior (Willner, 2005) . The apparatus was cleaned with a solution of 10% ethanol between tests in order to hide animal clues.
Western blotting
To quantify GluA1, PSD-95 and synapsin immunocontents, Western blot analyses were performed as previously described (Gonçalves et al., 2013; Neis et al., 2016) . Animals were euthanized by rapid decapitation and PFC was quickly dissected and snap-frozen with liquid nitrogen prior to storage at −80°C until use. Briefly, samples were mechanically homogenized in 300 μl of 50 mM Tris pH 7.0, 1 mM EDTA, 100 mM NaF, 0.1 mM PMSF, 2 mM Na3VO4, 1% Triton X-100, 10% glycerol, and Amresco Protease Inhibitor Cocktail catalog number M222 (working concentration: 0.5 mM AEBSF, 0.3 μM Aprotinin, 10 μM Bestatin, 10 μM E-64, 10 μM Leupeptin, 50 μM EDTA). Lysates were centrifuged (10,000g for 10 min, at 4°C) to eliminate cellular debris. The supernatants were diluted 1/1 (v/v) in 100 mM Tris pH 6.8, 4 mM EDTA and 8% SDS, followed by boiling for 5 min. Thereafter, sample dilution (40% glycerol, 100 mM Tris, bromophenol blue, pH 6.8) in the ratio 25:100 (v/v) and β-mercaptoethanol (final concentration 8%) were added to each sample. Protein content was quantified using bovine serum albumin as a standard (Peterson, 1977) . The same amount of protein (60 μg per lane) for each sample was electrophoresed in 10% SDS-PAGE minigels and transferred to nitrocellulose membranes using a semi-dry blotting apparatus (1.2 mA/cm 2 ; 1.5 h). To verify transfer efficiency process, membranes were stained with Ponceau Stain. The membranes were blocked with 5% bovine serum albumin (BSA) in TBS (10 mM Tris, 150 mM NaCl, pH 7.5). GluA1, PSD-95, synapsin and β-actin (loading control) immunocontents were detected after overnight incubation with specific antibodies diluted in TBS-T containing 2% BSA. The primary rabbit-antibodies were diluted 1:1000 for GluA1 (Santa Cruz Biotechnology), PSD-95 and synapsin (Cell Signaling Technology) and 1:2000 for with mouse anti-β-actin (Santa Cruz Biotechnology). Membranes were incubated for 1 h at room temperature with horseradish peroxidase (HRP)-conjugated anti-rabbit or antimouse antibody (1:5000, Millipore) for protein detection. The reactions were developed by chemiluminescence substrate (LumiGLO). All blocking and incubation steps were followed by washing 3 times (5 min) with TBS-T (10 mM Tris, 150 mM NaCl, 0.1% Tween-20, pH 7.5). The immunocontent of GluA1, PSD-95, synapsin were determined as a ratio of optical density (O.D.) of GluA1, PSD-95, synapsin band/O.D. of the β-actin band. The bands were quantified using Scion Image® software.
Statistical analysis
All data are presented as mean + SEM. Differences among experimental groups were determined by two-way ANOVA followed by Duncan's post hoc test, when appropriate. A value of p b 0.05 was considered to be significant. CUS procedure X treatment interaction [F (3,58) = 5.61, p b 0.01]. Post hoc analyses indicated that CUS exposure significantly increased the immobility time in the TST, as compared to control mice. Acute administration of both agmatine and ketamine was able to reverse the stressinduced increase in immobility time (p b 0.01). However, in nonstressed mice, only ketamine caused a reduction in the immobility time in the mouse TST (p b 0.05).
Locomotor activity
The OFT was conducted to rule out the possibility of an interference of CUS and/or treatments in the locomotor activity of mice. The twoway ANOVA revealed no differences for CUS procedure [F (1,58) = 2.22, p = 0.14], treatment [F (3,58) = 0.18, p = 0.91] and CUS procedure X treatment interaction [F (3,58) = 0.16, p = 0.92], indicating that none of the experimental conditions affected ambulation of mice (Fig. 2B) .
Splash test
As illustrated in Fig. 3A concerning the time to start the first grooming, the two-way ANOVA revealed no significant main effects for CUS procedure [F (1,58) 
Biochemical analyses
The effects of CUS and/or treatments with a single dose of agmatine, ketamine or fluoxetine in the immunocontent of synaptic proteins 
Discussion
Agmatine is an endogenous cationic amine involved in the modulation of several processes implicated in neurological disorders such as inflammation, oxidative stress and apoptosis. Moreover, the ability of this molecule to induce a response to neurotrophic factors seems to significantly contribute to the stimulation of a regenerative response in the central nervous system (Kuo et al., 2011; Li et al., 2006) . Considering that the modulation of neuroprotective and trophic mechanisms plays a key role in the efficacy of drugs and compounds with antidepressant properties, we have investigated the effects of agmatine in distinct animal models of depression. However, despite our previous observation that a single administration of this compound is able to reverse behavioral and biochemical alterations induced by an acute restraint stress , it remains to be investigated whether a single dose of agmatine is capable of counteracting the depressive-like behavior induced by chronic stress.
CUS is a widely used and well-recognized animal model of depression that results in multiple behavioral alterations, including an increase in the immobility time of mice in the TST (Kumar et al., 2011; Lu et al., 2006; Manosso et al., 2016; Moretti et al., 2012; Nirmal et al., 2008) . The TST is one of the most frequently used animal tests to assess compounds with antidepressant properties (Steru et al., 1985) and it is also useful to assess the depressive-like behavior induced by the administration of tumor necrosis factor-alpha (TNF-α) corticosterone (Pazini et al., 2015; Rosa et al., 2014) lipopolysaccharide (LPS) (Gawali et al., 2016; Zhu et al., 2016) , and 1-Methyl-4-phenylpyridinium [MPP(+)] , as well as by the exposure to unpredictable chronic mild stress (Moretti et al., 2012; Tao et al., 2016) and acute restraint stress (Sulakhiya et al., 2016) . Accordingly in the present study, the exposure to CUS led to an increased immobility time of mice in the TST. Interestingly, a single administration of agmatine was capable of reversing CUS-induced depressive-like behavior, an effect comparable to the one elicited by ketamine. Since fluoxetine was not able to elicit this antidepressant-like response in our study, it is reasonable to speculate that this effect elicited by agmatine is related to the fact that this compound shares more similarities with fast-acting antidepressants than with conventional monoaminergicbased drugs, regarding its ability to modulate molecular targets implicated in fast antidepressant responses. This hypothesis is in agreement with our previous study that showed that mTOR-mediated signaling pathways and AMPA receptors are activated by the acute administration of agmatine (Neis et al., 2016) .
In addition to alterations in the immobility time in the TST, many studies have reported that CUS reduces sucrose consumption and selfcare in rodents, which are parameters interpreted as anhedonic behavior (Garcia et al., 2009; Isingrini et al., 2010; Willner et al., 1987) , a key symptom often present in depressive individuals (Gold, 2015) . Although anhedonic behavior can be observed in several animal models of depression, in our study this alteration was not observed. The absence of an anhedonic-like behavior in CUS-exposed female mice observed in the present study may be related to sex-specific influence. It is interesting to note that the increased sucrose preference induced by ketamine in male rats was not reproducible in female rats (Carrier and Kabbaj, 2013) . Additionally 7 weeks of isolation stress in adulthood was reported to induce a strong anhedonia-like behavior in male rats, but not females (Sarkar and Kabbaj, 2016) . Another possible explanation for our results may be the fact that we used a mild stress protocol (14 days), while most studies investigating chronic stress use protocols of longer duration (i.e. 21 or 28 days). Indeed, there are discrepancies in studies investigating animal models of chronic stress, which may be related to differences in experimental conditions, including the duration and intensity of stressors, age, sex and lineage of animals, time of analysis and other variations in the protocols Gupta et al., 2014) . Therefore, future studies are warranted to elucidate the influence of agmatine in the anhedonic behavior of mice submitted to a more stressful experimental protocol in male and female mice.
As previously mentioned, the antidepressant-like effect afforded by a single administration of agmatine in the TST presents similarities with the mechanisms underlying the antidepressant properties of ketamine, including the modulation of glutamatergic transmission (particularly the stimulation of AMPA signaling and NMDA receptors inhibition), a rapid increase in BDNF levels and the stimulation of mTOR-dependent synthesis of synaptic proteins in the PFC of mice, effects demonstrated after 60 min of agmatine administration Neis et al., 2016; Neis et al., 2015) . In addition, a recent study demonstrated that agmatine induces a rapid antidepressant-like effect in the Crtc1 −/− knockout mouse model of depression by inhibiting NMDA receptors activity and causing a rapid increase in BDNF levels and synaptogenesis (Meylan et al., 2016) . However, in the present study, we did not find any alteration induced by CUS and/or treatments in the levels of synaptic proteins (i.e. GluA1, PSD-95 and synapsin) in the PFC of mice. One possible explanation for these results may be the fact that, the antidepressant-like effects induced by ketamine and agmatine in the present study were a consequence of changes that occurred in time points that preceded the Western blot analyses. As previously mentioned, we have recently found increased levels of PSD-95 and GluA1 60 min after a single administration of agmatine (Neis et al., 2016) , reinforcing the hypothesis that the antidepressant-like effect observed in the TST may be related to an acute synaptic stimulation that was not maintained for a prolonged period of time. Additionally, our findings were conflicting with studies showing that ketamine is able to increase levels of synaptic proteins of rats at the same time point investigated (24 h after administration) (Hermes et al., 2011; Li et al., 2011) . However, this discrepancy may be explained by the fact that we used different species (Swiss mice rather than rats), doses (1 mg/kg rather than 10 mg/kg) and routes of administration (oral route rather than intraperitoneal route). However, we cannot rule out the possibility of the occurrence of synaptic alterations in other brain structures. In spite of the limitations regarding the absence of anhedonic behavior and neuronal markers in CUS-exposed mice, the results showed herein clearly indicate the behavioral similarities between the beneficial effects of agmatine and ketamine on CUS procedure. Thus, new studies are warranted to exactly determine whether ketamine and agmatine are able to alter the levels of synaptic proteins using the same stress protocol employed here, but at distinct time points and/or in male animals. Furthermore, we also should not rule out the possibility that such alterations may occur in other brain structures that are affected by CUS, particularly the hippocampus.
Conclusion
The identification of fast-acting antidepressants that do not present the drawbacks of ketamine (i.e. psychotomimetic effects, tolerance and toxicity) will be a significant advance for the treatment of depressive disorders. A valuable approach to conduct this screening is through the investigation of the antidepressant-like properties of compounds that share similar mechanisms with ketamine. In this context, recent studies have been suggesting that agmatine acts by modulating molecular mechanisms related to synaptic plasticity, similar to ketamine. In the present study, we further reinforced this hypothesis by showing that a single administration of agmatine, similarly to ketamine, is able to reverse the depressive-like phenotype induced by a chronic stress protocol in the TST, not responsive to fluoxetine. Although we could not find alterations in the levels of synaptic proteins evaluated in the present study (i.e. GluA1, PSD-95 and synapsin; 24 h after treatment), future studies will be necessary to elucidate whether the behavioral effects observed here are a consequence of alterations in the levels of these proteins at distinct time points and/or in other brain structures, particularly the hippocampus.
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